- 2024-08-20 02:14抑制剂TC-DAPK 6|TC-DAPK 6|315694-89-4|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂TC-G-1008|TC-G-1008|1621175-65-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂TCH-165|TCH-165|1446350-60-2|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:14抑制剂TCH-165|TCH-165|1446350-60-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂TC13172|TC13172|2093393-05-4|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:14抑制剂TC13172|TC13172|2093393-05-4|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂TC-DAPK 6|TC-DAPK 6|315694-89-4|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:14抑制剂TC-DAPK 6|TC-DAPK 6|315694-89-4|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:14抑制剂TC HSD 21|TC HSD 21|330203-01-5|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:14抑制剂TC HSD 21|TC HSD 21|330203-01-5|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂TC13172|TC13172|2093393-05-4|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:14抑制剂TC HSD 21|TC HSD 21|330203-01-5|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:14抑制剂TB5|TB5|948841-07-4|Adamas life|≥99%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂TBK1/IKKε-IN-4|TBK1/IKKε-IN-4|1381930-17-1|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:14抑制剂TBK1/IKKε-IN-4|TBK1/IKKε-IN-4|1381930-17-1|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂Tazarotenic acid|Tazarotenic acid|118292-41-4|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂TB5|TB5|948841-07-4|Adamas life|≥99%（以实测数值为准）|BR|100mg
- 2024-08-20 02:14抑制剂TB5|TB5|948841-07-4|Adamas life|≥99%（以实测数值为准）|BR|25mg
- 2024-08-20 02:14抑制剂Tasosartan|Tasosartan|145733-36-4|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:14抑制剂Tazarotenic acid|Tazarotenic acid|118292-41-4|Adamas life|≥98%（以实测数值为准）|BR|1mg
